CA2699504C - Tetrahydroquinoline derivatives for treating post-traumatic stress disorders - Google Patents

Tetrahydroquinoline derivatives for treating post-traumatic stress disorders Download PDF

Info

Publication number
CA2699504C
CA2699504C CA2699504A CA2699504A CA2699504C CA 2699504 C CA2699504 C CA 2699504C CA 2699504 A CA2699504 A CA 2699504A CA 2699504 A CA2699504 A CA 2699504A CA 2699504 C CA2699504 C CA 2699504C
Authority
CA
Canada
Prior art keywords
formula
pharmaceutically acceptable
phenyl
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2699504A
Other languages
English (en)
French (fr)
Other versions
CA2699504A1 (en
Inventor
Francois Jenck
Original Assignee
Actelion Pharmaceuticals Ltd
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40467356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2699504(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd, Idorsia Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CA2699504A1 publication Critical patent/CA2699504A1/en
Application granted granted Critical
Publication of CA2699504C publication Critical patent/CA2699504C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2699504A 2007-10-10 2008-10-09 Tetrahydroquinoline derivatives for treating post-traumatic stress disorders Active CA2699504C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IB2007054130 2007-10-10
IBPCT/IB2007/054130 2007-10-10
PCT/IB2008/054138 WO2009047723A2 (en) 2007-10-10 2008-10-09 Tetrahydroquinoline derivatives for treating post-traumatic stress disorders

Publications (2)

Publication Number Publication Date
CA2699504A1 CA2699504A1 (en) 2009-04-16
CA2699504C true CA2699504C (en) 2015-11-24

Family

ID=40467356

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2699504A Active CA2699504C (en) 2007-10-10 2008-10-09 Tetrahydroquinoline derivatives for treating post-traumatic stress disorders

Country Status (27)

Country Link
US (1) US9532985B2 (enExample)
EP (1) EP2207550B1 (enExample)
JP (1) JP5883222B2 (enExample)
KR (1) KR101733247B1 (enExample)
CN (1) CN101820878B (enExample)
AR (1) AR068768A1 (enExample)
AU (1) AU2008309194B2 (enExample)
BR (1) BRPI0818617A2 (enExample)
CA (1) CA2699504C (enExample)
CY (1) CY1114799T1 (enExample)
DK (1) DK2207550T3 (enExample)
EA (1) EA017443B1 (enExample)
ES (1) ES2444418T3 (enExample)
HR (1) HRP20140214T1 (enExample)
IL (1) IL204838A (enExample)
MA (1) MA31800B1 (enExample)
MX (1) MX2010003711A (enExample)
MY (1) MY153044A (enExample)
NZ (1) NZ585086A (enExample)
PE (1) PE20091010A1 (enExample)
PL (1) PL2207550T3 (enExample)
PT (1) PT2207550E (enExample)
SI (1) SI2207550T1 (enExample)
TW (1) TWI428129B (enExample)
UA (1) UA99150C2 (enExample)
WO (1) WO2009047723A2 (enExample)
ZA (1) ZA201003251B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2380391T3 (es) 2006-12-22 2012-05-11 Actelion Pharmaceuticals Ltd. Derivados de 5,6,7,8-tetrahidro-imidazo[1,5-a]pirazina
US20110105514A1 (en) 2008-06-25 2011-05-05 Hamed Aissaoui 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine compounds
EP2402322A1 (en) 2010-07-02 2012-01-04 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisoquinoline derivative and its use as orexin receptor antagonist
TW201209037A (en) 2010-08-24 2012-03-01 Actelion Pharmaceuticals Ltd Proline sulfonamide derivatives as orexin receptor antagonists
SI2626350T1 (sl) 2010-09-22 2015-09-30 Eisai R&D Management Co., Ltd. Spojina ciklopropana
WO2012063207A1 (en) 2010-11-10 2012-05-18 Actelion Pharmaceuticals Ltd Lactam derivatives useful as orexin receptor antagonists
WO2012085852A1 (en) 2010-12-22 2012-06-28 Actelion Pharmaceuticals Ltd 3,8-diaza-bicyclo[4.2.0]oct-8-yl amides
WO2012110986A1 (en) 2011-02-18 2012-08-23 Actelion Pharmaceuticals Ltd Novel pyrazole and imidazole derivatives useful as orexin antagonists
WO2012114252A1 (en) 2011-02-21 2012-08-30 Actelion Pharmaceuticals Ltd Novel indole and pyrrolopyridine amides
WO2013050938A1 (en) 2011-10-04 2013-04-11 Actelion Pharmaceuticals Ltd 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7-diazabicyclo[3.3.1]nonane derivatives
DK2776430T3 (en) 2011-11-08 2016-05-09 Actelion Pharmaceuticals Ltd 2- (1,2,3-triazol-2-yl) benzamide and 3- (1,2,3-triazol-2-yl) PICOLINAMIDDERIVATER AS orexin receptor antagonists
TWI570120B (zh) 2012-06-04 2017-02-11 艾克泰聯製藥有限公司 苯并咪唑脯胺酸衍生物
AU2013328301A1 (en) 2012-10-10 2015-05-28 Actelion Pharmaceuticals Ltd Orexin receptor antagonists which are [ortho bi (hetero-)aryl]-[2-(meta bi (hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives
CN105051040A (zh) 2013-03-12 2015-11-11 埃科特莱茵药品有限公司 作为食欲素受体拮抗剂的氮杂环丁烷酰胺衍生物
JP6496733B2 (ja) 2013-12-03 2019-04-03 イドーシア ファーマシューティカルズ リミテッドIdorsia Pharmaceuticals Ltd (s)−(2−(6−クロロ−7−メチル−1h−ベンゾ[d]イミダゾール−2−イル)−2−メチルピロリジン−1−イル)(5−メトキシ−2−(2h−1,2,3−トリアゾール−2−イル)フェニル)メタノンの結晶形及びオレキシン受容体アンタゴニストとしてのその使用
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
KR102330133B1 (ko) 2013-12-04 2021-11-23 이도르시아 파마슈티컬스 리미티드 벤즈이미다졸-프롤린 유도체의 용도
SG10202007759RA (en) 2014-10-23 2020-09-29 Eisai R&D Man Co Ltd Compositions and methods for treating insomnia
CN115710250A (zh) * 2017-08-01 2023-02-24 博健制药有限责任公司 一种食欲素受体拮抗剂的晶型及其制备方法和用途
WO2020007964A1 (en) 2018-07-05 2020-01-09 Idorsia Pharmaceuticals Ltd 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives
WO2020007977A1 (en) 2018-07-06 2020-01-09 Idorsia Pharmaceuticals Ltd 7-trifluoromethyl-[1,4]diazepan derivatives
WO2020099511A1 (en) 2018-11-14 2020-05-22 Idorsia Pharmaceuticals Ltd Benzimidazole-2-methyl-morpholine derivatives
TW202400149A (zh) 2022-05-13 2024-01-01 瑞士商愛杜西亞製藥有限公司 經噻唑并芳基-甲基取代之環狀肼-n-甲醯胺衍生物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6011301A (en) * 2000-03-14 2001-09-24 Actelion Pharmaceuticals Ltd 1,2,3,4-tetrahydroisoquinoline derivatives
AU2004224156B2 (en) * 2003-03-26 2010-08-12 Actelion Pharmaceuticals Ltd. Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists
JP4094050B2 (ja) * 2004-03-01 2008-06-04 アクテリオン ファーマシューティカルズ リミテッド 置換1,2,3,4−テトラヒドロイソキノリン誘導体
US7501395B2 (en) * 2005-04-25 2009-03-10 Eisai R & D Management Co., Ltd. Method of screening for antianxiety drugs
EP1998774A1 (en) 2006-03-15 2008-12-10 Actelion Pharmaceuticals Ltd. Tetrahydroisoquinoline derivatives to enhance memory function
EP2402322A1 (en) 2010-07-02 2012-01-04 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisoquinoline derivative and its use as orexin receptor antagonist

Also Published As

Publication number Publication date
KR101733247B1 (ko) 2017-05-08
SI2207550T1 (sl) 2014-03-31
EA017443B1 (ru) 2012-12-28
US9532985B2 (en) 2017-01-03
ES2444418T3 (es) 2014-02-25
AR068768A1 (es) 2009-12-02
CN101820878B (zh) 2012-02-01
HK1145440A1 (en) 2011-04-21
CY1114799T1 (el) 2016-12-14
CN101820878A (zh) 2010-09-01
KR20100065203A (ko) 2010-06-15
WO2009047723A3 (en) 2009-05-28
WO2009047723A2 (en) 2009-04-16
MY153044A (en) 2014-12-31
ZA201003251B (en) 2011-07-27
PE20091010A1 (es) 2009-08-08
EP2207550A2 (en) 2010-07-21
DK2207550T3 (da) 2014-01-27
MA31800B1 (fr) 2010-10-01
JP5883222B2 (ja) 2016-03-09
IL204838A0 (en) 2010-11-30
AU2008309194A1 (en) 2009-04-16
TWI428129B (zh) 2014-03-01
NZ585086A (en) 2012-03-30
US20100234420A1 (en) 2010-09-16
AU2008309194B2 (en) 2013-10-03
CA2699504A1 (en) 2009-04-16
EA201000557A1 (ru) 2010-10-29
TW200932231A (en) 2009-08-01
MX2010003711A (es) 2010-04-30
IL204838A (en) 2014-09-30
PT2207550E (pt) 2014-02-07
PL2207550T3 (pl) 2014-05-30
HRP20140214T1 (hr) 2014-04-11
UA99150C2 (ru) 2012-07-25
EP2207550B1 (en) 2013-12-11
JP2011500550A (ja) 2011-01-06
BRPI0818617A2 (pt) 2015-04-07

Similar Documents

Publication Publication Date Title
AU2008309194B2 (en) Tetrahydroquinoline derivatives for treating post-traumatic stress disorders
CN115154467B (zh) 治疗肝纤维化的方法
JP5582535B2 (ja) 点眼投与による神経疾患または精神神経疾患の治療または予防
US20100249164A1 (en) Modulation of sleep with nr2b receptor antagonists
KR20100016270A (ko) 비맥각계의 선택적 d2 수용체 작용제를 유효 성분으로서 함유하는 후안부 질환의 예방 또는 치료제
MXPA00013033A (es) Sulfonamidas que contienen isoesteres n-heterociclicos para las enfermedades de la vision y la memoria.
WO2004035000A2 (en) Enhancement of sleep with t-type calcium channel antagonists
EP1113797A4 (en) TREATMENT OF PERSISTENT PAIN
JP2008542417A (ja) 進行性ミオクローヌスてんかんに特徴付けられる疾患の治療用ブリバラセタムの使用
EP2716302A1 (en) Prophylactic or therapeutic agent for neuropathic pain associated with guillain-barre syndrome
IL262920A (en) A triangular combination of pure 5 – ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor agonists
HK1145440B (en) Tetrahydroquinoline derivatives for treating post-traumatic stress disorders
JP2007519733A (ja) アンパカインにより誘導されるシナプス応答促通のコリンエステラーゼ阻害剤による増強方法
KR980008226A (ko) 시각기능장애의 예방 및 치료제
WO2005023256A1 (en) Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
ZA200308020B (en) Pharmaceutically active compounds and methods of use
JP2002522525A (ja) 視力および記憶障害のための複素環チオエステルまたはケトン
CN1499974A (zh) 伴有前列腺肥大症的膀胱刺激症状治疗药
Sévoz-Couche et al. Antinociceptive effect of cardiopulmonary chemoreceptor and baroreceptor reflex activation in the rat
MXPA00013031A (es) Ureas y carbamatos de acidos carboxilicos n-heterociclicos e isoesteres, para las enfermedades de la vision y la memoria.
JP2014525474A (ja) 光過敏性てんかんの予防または治療における使用のための1h−キナゾリン−2,4−ジオンの使用
Alkozi et al. Improving melatonin delivery within the eye
CA3018375C (en) Negative allosteric modulators of mglur5 for use in the treatment of mature brain damages

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130916

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250410